| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 75 | 2022 | 719 | 7.760 |
Why?
|
| Phosphoprotein Phosphatases | 20 | 2016 | 114 | 4.570 |
Why?
|
| Genes, p53 | 57 | 2013 | 213 | 4.380 |
Why?
|
| Neoplasms, Experimental | 24 | 2018 | 212 | 2.490 |
Why?
|
| Aging | 17 | 2017 | 1194 | 2.250 |
Why?
|
| Protein Phosphatase 2C | 21 | 2020 | 55 | 1.980 |
Why?
|
| DNA Repair | 15 | 2015 | 583 | 1.800 |
Why?
|
| DNA Damage | 22 | 2018 | 515 | 1.750 |
Why?
|
| Cell Transformation, Neoplastic | 18 | 2017 | 618 | 1.630 |
Why?
|
| Gene Expression Regulation, Neoplastic | 20 | 2021 | 1890 | 1.620 |
Why?
|
| Tumor Suppressor Proteins | 12 | 2018 | 470 | 1.370 |
Why?
|
| Neoplasms | 20 | 2022 | 2781 | 1.340 |
Why?
|
| Mice | 127 | 2022 | 17716 | 1.310 |
Why?
|
| Osteosarcoma | 10 | 2016 | 258 | 1.260 |
Why?
|
| Mutation | 39 | 2022 | 5790 | 1.220 |
Why?
|
| Longevity | 6 | 2009 | 138 | 1.190 |
Why?
|
| Genes, Tumor Suppressor | 9 | 2014 | 203 | 1.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 9 | 2020 | 94 | 1.150 |
Why?
|
| Loss of Heterozygosity | 12 | 2019 | 124 | 1.070 |
Why?
|
| Cell Cycle Proteins | 9 | 2014 | 645 | 1.050 |
Why?
|
| Animals | 139 | 2022 | 34094 | 1.030 |
Why?
|
| Bone Neoplasms | 9 | 2017 | 429 | 0.960 |
Why?
|
| Neoplasm Proteins | 12 | 2006 | 669 | 0.950 |
Why?
|
| Mice, Knockout | 43 | 2015 | 3747 | 0.910 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 12 | 2013 | 80 | 0.910 |
Why?
|
| Disease Models, Animal | 22 | 2022 | 4344 | 0.890 |
Why?
|
| Cell Cycle | 11 | 2015 | 619 | 0.870 |
Why?
|
| Mammary Neoplasms, Experimental | 12 | 2010 | 244 | 0.860 |
Why?
|
| Cell Proliferation | 12 | 2020 | 2305 | 0.770 |
Why?
|
| Carcinogens | 9 | 2007 | 153 | 0.750 |
Why?
|
| Signal Transduction | 17 | 2017 | 4520 | 0.750 |
Why?
|
| Animals, Genetically Modified | 4 | 2014 | 315 | 0.750 |
Why?
|
| Mice, Transgenic | 41 | 2015 | 2412 | 0.740 |
Why?
|
| DNA-Binding Proteins | 13 | 2016 | 2056 | 0.730 |
Why?
|
| Serine | 3 | 2020 | 174 | 0.730 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2020 | 59 | 0.670 |
Why?
|
| Nuclear Proteins | 10 | 2013 | 1271 | 0.650 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 69 | 0.640 |
Why?
|
| Cellular Senescence | 8 | 2011 | 162 | 0.630 |
Why?
|
| Proto-Oncogene Proteins | 15 | 2013 | 551 | 0.620 |
Why?
|
| Apoptosis | 17 | 2017 | 1791 | 0.610 |
Why?
|
| Zebrafish Proteins | 6 | 2000 | 105 | 0.610 |
Why?
|
| Mice, Inbred C57BL | 33 | 2018 | 4418 | 0.610 |
Why?
|
| Lymphoma | 8 | 2011 | 322 | 0.600 |
Why?
|
| Histones | 5 | 2015 | 539 | 0.570 |
Why?
|
| Phosphorylation | 14 | 2020 | 1623 | 0.570 |
Why?
|
| Fibroblasts | 10 | 2013 | 891 | 0.570 |
Why?
|
| Heterozygote | 19 | 2010 | 678 | 0.560 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2015 | 528 | 0.550 |
Why?
|
| DNA Breaks, Double-Stranded | 3 | 2015 | 134 | 0.510 |
Why?
|
| Carcinoma | 4 | 2013 | 280 | 0.480 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2013 | 156 | 0.470 |
Why?
|
| Phenotype | 15 | 2022 | 4248 | 0.450 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2009 | 342 | 0.450 |
Why?
|
| Recombination, Genetic | 10 | 2007 | 447 | 0.440 |
Why?
|
| Carcinogenicity Tests | 6 | 2009 | 20 | 0.430 |
Why?
|
| Alleles | 19 | 2015 | 1614 | 0.430 |
Why?
|
| Gene Silencing | 2 | 2018 | 237 | 0.430 |
Why?
|
| Mice, Mutant Strains | 9 | 2014 | 388 | 0.420 |
Why?
|
| Humans | 93 | 2022 | 124083 | 0.420 |
Why?
|
| Base Sequence | 30 | 2016 | 3093 | 0.410 |
Why?
|
| Gene Expression Profiling | 6 | 2015 | 1691 | 0.400 |
Why?
|
| Cell Line, Tumor | 16 | 2018 | 3329 | 0.390 |
Why?
|
| Germ-Line Mutation | 2 | 2014 | 321 | 0.390 |
Why?
|
| Gene Deletion | 7 | 2009 | 793 | 0.390 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 96 | 0.390 |
Why?
|
| Lung Neoplasms | 4 | 2017 | 1601 | 0.380 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 113 | 0.380 |
Why?
|
| Stem Cells | 9 | 2011 | 702 | 0.380 |
Why?
|
| Oncogenes | 2 | 2022 | 168 | 0.370 |
Why?
|
| Models, Biological | 9 | 2013 | 1461 | 0.370 |
Why?
|
| RNA, Messenger | 12 | 2014 | 2820 | 0.360 |
Why?
|
| Inflammation | 2 | 2017 | 1413 | 0.360 |
Why?
|
| Mutagens | 2 | 2001 | 84 | 0.350 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2009 | 81 | 0.350 |
Why?
|
| Sarcoma, Experimental | 5 | 2015 | 16 | 0.340 |
Why?
|
| MicroRNAs | 5 | 2019 | 837 | 0.340 |
Why?
|
| Genetic Engineering | 2 | 2009 | 161 | 0.340 |
Why?
|
| Molecular Sequence Data | 31 | 2016 | 3872 | 0.330 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2009 | 11 | 0.320 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 45 | 0.320 |
Why?
|
| Genetic Predisposition to Disease | 10 | 2013 | 3124 | 0.320 |
Why?
|
| Wnt Signaling Pathway | 3 | 2016 | 197 | 0.320 |
Why?
|
| Ultraviolet Rays | 7 | 2013 | 205 | 0.320 |
Why?
|
| Protein Kinases | 3 | 2006 | 332 | 0.310 |
Why?
|
| Sequence Deletion | 5 | 2002 | 528 | 0.310 |
Why?
|
| Colorectal Neoplasms | 2 | 2013 | 565 | 0.310 |
Why?
|
| Cyclins | 7 | 2002 | 101 | 0.310 |
Why?
|
| Adenocarcinoma | 5 | 2016 | 996 | 0.300 |
Why?
|
| Genetic Vectors | 10 | 2010 | 941 | 0.300 |
Why?
|
| Peptide Fragments | 2 | 2013 | 750 | 0.300 |
Why?
|
| Biomarkers, Tumor | 3 | 2017 | 1450 | 0.300 |
Why?
|
| DNA, Viral | 8 | 1997 | 481 | 0.290 |
Why?
|
| DNA | 5 | 2010 | 1597 | 0.290 |
Why?
|
| HIV-1 | 6 | 1997 | 463 | 0.290 |
Why?
|
| Oncogene Proteins | 1 | 2008 | 137 | 0.290 |
Why?
|
| RNA, Neoplasm | 3 | 2019 | 139 | 0.280 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2005 | 100 | 0.280 |
Why?
|
| Mammary Glands, Animal | 5 | 2007 | 483 | 0.280 |
Why?
|
| Genes, ras | 7 | 2017 | 97 | 0.270 |
Why?
|
| Retroviridae | 6 | 2003 | 196 | 0.270 |
Why?
|
| Stress, Physiological | 2 | 2009 | 258 | 0.270 |
Why?
|
| Morphogenesis | 1 | 2007 | 211 | 0.270 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2011 | 547 | 0.270 |
Why?
|
| Genotype | 18 | 2022 | 2548 | 0.270 |
Why?
|
| Tumor Suppressor Protein p14ARF | 2 | 2003 | 7 | 0.260 |
Why?
|
| Cell Division | 12 | 2002 | 784 | 0.260 |
Why?
|
| Transfection | 10 | 2007 | 1068 | 0.260 |
Why?
|
| Trans-Activators | 4 | 2013 | 808 | 0.260 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2010 | 553 | 0.260 |
Why?
|
| Cyclin D1 | 3 | 2003 | 112 | 0.250 |
Why?
|
| Gene Amplification | 4 | 2015 | 228 | 0.250 |
Why?
|
| Cisplatin | 2 | 2018 | 243 | 0.250 |
Why?
|
| Homeostasis | 5 | 2010 | 689 | 0.250 |
Why?
|
| Genetic Techniques | 2 | 2003 | 106 | 0.250 |
Why?
|
| Tamoxifen | 3 | 2012 | 363 | 0.240 |
Why?
|
| HEK293 Cells | 4 | 2020 | 744 | 0.230 |
Why?
|
| Embryonic and Fetal Development | 3 | 2002 | 132 | 0.230 |
Why?
|
| DNA Glycosylases | 1 | 2004 | 32 | 0.230 |
Why?
|
| Gene Dosage | 5 | 2001 | 441 | 0.230 |
Why?
|
| Liver Neoplasms | 6 | 2017 | 1315 | 0.230 |
Why?
|
| Cells, Cultured | 14 | 2013 | 3054 | 0.230 |
Why?
|
| Crosses, Genetic | 11 | 2004 | 162 | 0.220 |
Why?
|
| Methylnitrosourea | 2 | 2000 | 19 | 0.220 |
Why?
|
| Isoenzymes | 1 | 2004 | 227 | 0.220 |
Why?
|
| Mice, 129 Strain | 3 | 2014 | 98 | 0.220 |
Why?
|
| Point Mutation | 4 | 2004 | 348 | 0.220 |
Why?
|
| Doxorubicin | 4 | 2018 | 301 | 0.210 |
Why?
|
| Drosophila melanogaster | 1 | 2009 | 763 | 0.210 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 4 | 2010 | 12 | 0.210 |
Why?
|
| Drosophila Proteins | 1 | 2009 | 717 | 0.210 |
Why?
|
| Phosphopeptides | 2 | 2020 | 27 | 0.210 |
Why?
|
| Li-Fraumeni Syndrome | 4 | 2014 | 41 | 0.200 |
Why?
|
| Female | 45 | 2018 | 66156 | 0.200 |
Why?
|
| Homozygote | 8 | 2015 | 532 | 0.200 |
Why?
|
| Calculi | 1 | 2022 | 15 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 11 | 2005 | 1583 | 0.200 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 4 | 2006 | 131 | 0.200 |
Why?
|
| Machine Learning | 2 | 2022 | 238 | 0.200 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2009 | 357 | 0.200 |
Why?
|
| Hematopoiesis | 2 | 2018 | 218 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 8 | 2017 | 1064 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2011 | 100 | 0.190 |
Why?
|
| Stomach Neoplasms | 3 | 2007 | 540 | 0.190 |
Why?
|
| Nitrosamines | 3 | 2007 | 18 | 0.190 |
Why?
|
| Immune System | 1 | 2002 | 87 | 0.190 |
Why?
|
| Neoplasm Metastasis | 5 | 2016 | 657 | 0.190 |
Why?
|
| Gene Targeting | 5 | 2003 | 178 | 0.180 |
Why?
|
| Transcription Factors | 6 | 2016 | 2596 | 0.180 |
Why?
|
| Phosphoproteins | 3 | 2009 | 403 | 0.180 |
Why?
|
| Genome, Human | 3 | 2018 | 1272 | 0.180 |
Why?
|
| Genomic Instability | 4 | 2016 | 229 | 0.180 |
Why?
|
| Mitosis | 5 | 2004 | 238 | 0.180 |
Why?
|
| Gene Expression Regulation | 8 | 2009 | 2535 | 0.180 |
Why?
|
| RNA, Small Interfering | 5 | 2015 | 671 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 130 | 0.170 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2020 | 35 | 0.170 |
Why?
|
| Testis | 3 | 2015 | 412 | 0.170 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2012 | 116 | 0.170 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2012 | 254 | 0.170 |
Why?
|
| Breast Neoplasms | 5 | 2009 | 2489 | 0.170 |
Why?
|
| Mutagenesis | 4 | 2000 | 347 | 0.170 |
Why?
|
| Reproduction | 1 | 2002 | 243 | 0.170 |
Why?
|
| Gene Rearrangement | 2 | 2021 | 320 | 0.170 |
Why?
|
| Genes, Retinoblastoma | 3 | 1997 | 18 | 0.160 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2000 | 137 | 0.160 |
Why?
|
| Sarcoma | 1 | 2022 | 194 | 0.160 |
Why?
|
| Protein Stability | 1 | 2020 | 165 | 0.160 |
Why?
|
| Thymus Neoplasms | 4 | 2004 | 29 | 0.160 |
Why?
|
| Male | 37 | 2018 | 60804 | 0.160 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2013 | 265 | 0.160 |
Why?
|
| MCF-7 Cells | 1 | 2020 | 221 | 0.160 |
Why?
|
| Blotting, Western | 6 | 2013 | 1107 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 1289 | 0.160 |
Why?
|
| T-Lymphocytes | 7 | 2015 | 1696 | 0.160 |
Why?
|
| Cell Line | 14 | 2010 | 2779 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 6 | 2002 | 82 | 0.160 |
Why?
|
| Skin Aging | 2 | 2011 | 14 | 0.160 |
Why?
|
| Rhabdomyosarcoma | 1 | 2022 | 201 | 0.160 |
Why?
|
| Disease Progression | 4 | 2012 | 2037 | 0.160 |
Why?
|
| Ligases | 1 | 1998 | 46 | 0.160 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 13 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2015 | 1014 | 0.160 |
Why?
|
| Aging, Premature | 2 | 2013 | 31 | 0.160 |
Why?
|
| Models, Genetic | 6 | 2022 | 760 | 0.150 |
Why?
|
| Clone Cells | 1 | 2018 | 166 | 0.150 |
Why?
|
| Wnt1 Protein | 6 | 2010 | 71 | 0.150 |
Why?
|
| Wnt Proteins | 6 | 2000 | 195 | 0.150 |
Why?
|
| Organ Specificity | 4 | 2010 | 425 | 0.150 |
Why?
|
| Recombinational DNA Repair | 1 | 2018 | 19 | 0.150 |
Why?
|
| ras Proteins | 2 | 2013 | 136 | 0.150 |
Why?
|
| Transcriptional Activation | 4 | 2015 | 483 | 0.150 |
Why?
|
| DNA Primers | 11 | 1998 | 660 | 0.150 |
Why?
|
| Sirtuins | 2 | 2009 | 20 | 0.150 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2000 | 275 | 0.150 |
Why?
|
| Aneuploidy | 2 | 1996 | 154 | 0.140 |
Why?
|
| Neuroblastoma | 2 | 2015 | 520 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1998 | 70 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2013 | 27 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2015 | 197 | 0.140 |
Why?
|
| Exome | 4 | 2015 | 1042 | 0.140 |
Why?
|
| Checkpoint Kinase 1 | 3 | 2006 | 24 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 85 | 0.140 |
Why?
|
| Quality Control | 1 | 2017 | 119 | 0.140 |
Why?
|
| Spleen | 2 | 2011 | 280 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 8 | 2014 | 1340 | 0.130 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 117 | 0.130 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2015 | 151 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 2 | 2016 | 1110 | 0.130 |
Why?
|
| Moloney murine leukemia virus | 3 | 1996 | 19 | 0.130 |
Why?
|
| Liver Neoplasms, Experimental | 2 | 2007 | 61 | 0.130 |
Why?
|
| Duodenal Neoplasms | 1 | 2016 | 21 | 0.130 |
Why?
|
| Gene Regulatory Networks | 2 | 2015 | 353 | 0.130 |
Why?
|
| Sezary Syndrome | 1 | 2015 | 12 | 0.130 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 9 | 0.130 |
Why?
|
| Amino Acid Sequence | 9 | 2005 | 2697 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2016 | 60 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2868 | 0.120 |
Why?
|
| Carrier Proteins | 2 | 2015 | 1022 | 0.120 |
Why?
|
| Endocrine Gland Neoplasms | 1 | 1995 | 6 | 0.120 |
Why?
|
| HeLa Cells | 4 | 2010 | 808 | 0.120 |
Why?
|
| Ghrelin | 1 | 2015 | 54 | 0.120 |
Why?
|
| Sirtuin 1 | 2 | 2013 | 47 | 0.120 |
Why?
|
| Uracil-DNA Glycosidase | 2 | 2004 | 5 | 0.120 |
Why?
|
| Skin Neoplasms | 3 | 2015 | 801 | 0.120 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2013 | 34 | 0.120 |
Why?
|
| Genes, vif | 1 | 1994 | 1 | 0.120 |
Why?
|
| Telomerase | 4 | 2014 | 162 | 0.120 |
Why?
|
| Dipeptides | 1 | 2015 | 59 | 0.120 |
Why?
|
| Cell Differentiation | 6 | 2015 | 1934 | 0.120 |
Why?
|
| Aminopyridines | 1 | 2015 | 53 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2014 | 938 | 0.120 |
Why?
|
| Transcriptome | 3 | 2015 | 927 | 0.120 |
Why?
|
| Phospholipases A2, Calcium-Independent | 1 | 2014 | 13 | 0.120 |
Why?
|
| Receptor, Notch1 | 1 | 2014 | 65 | 0.110 |
Why?
|
| Programming, Linear | 1 | 2014 | 4 | 0.110 |
Why?
|
| DNA, Neoplasm | 5 | 2007 | 301 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 165 | 0.110 |
Why?
|
| Mice, Inbred BALB C | 4 | 2009 | 1000 | 0.110 |
Why?
|
| HCT116 Cells | 2 | 2018 | 55 | 0.110 |
Why?
|
| Genes, pol | 2 | 1991 | 10 | 0.110 |
Why?
|
| Gamma Rays | 4 | 2010 | 49 | 0.110 |
Why?
|
| Biological Assay | 2 | 2005 | 100 | 0.110 |
Why?
|
| Sequence Homology, Nucleic Acid | 4 | 1994 | 286 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 1240 | 0.110 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2013 | 259 | 0.110 |
Why?
|
| Casein Kinase Idelta | 1 | 2013 | 5 | 0.110 |
Why?
|
| Protein Phosphatase 1 | 2 | 2006 | 50 | 0.110 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 22 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 36 | 0.100 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2013 | 54 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 4540 | 0.100 |
Why?
|
| S Phase | 1 | 2013 | 73 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 209 | 0.100 |
Why?
|
| CpG Islands | 2 | 2014 | 320 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 538 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 2 | 2016 | 681 | 0.100 |
Why?
|
| Gene Products, tax | 1 | 2013 | 46 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1674 | 0.100 |
Why?
|
| G1 Phase | 1 | 2013 | 67 | 0.100 |
Why?
|
| Body Weight | 3 | 2011 | 1008 | 0.100 |
Why?
|
| Membrane Proteins | 2 | 2016 | 1527 | 0.100 |
Why?
|
| Radiation, Ionizing | 2 | 2003 | 41 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2012 | 16 | 0.100 |
Why?
|
| Embryo, Mammalian | 4 | 2013 | 455 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 240 | 0.100 |
Why?
|
| Genes, myc | 4 | 1996 | 99 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2015 | 871 | 0.100 |
Why?
|
| Gene Frequency | 2 | 2013 | 718 | 0.100 |
Why?
|
| Chromosome Mapping | 4 | 2007 | 1082 | 0.100 |
Why?
|
| Osteoblasts | 3 | 2015 | 149 | 0.100 |
Why?
|
| Caloric Restriction | 2 | 2010 | 85 | 0.100 |
Why?
|
| Cell Nucleus | 2 | 2012 | 676 | 0.100 |
Why?
|
| Transcription, Genetic | 5 | 2007 | 1701 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1994 | 474 | 0.090 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2010 | 213 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2013 | 165 | 0.090 |
Why?
|
| Chromosomal Instability | 1 | 2011 | 58 | 0.090 |
Why?
|
| Circadian Rhythm | 2 | 2010 | 271 | 0.090 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 52 | 0.090 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 125 | 0.090 |
Why?
|
| Ribosomal Proteins | 1 | 2011 | 73 | 0.090 |
Why?
|
| Disease Susceptibility | 3 | 2007 | 299 | 0.090 |
Why?
|
| Sequence Alignment | 2 | 2004 | 625 | 0.090 |
Why?
|
| Exons | 3 | 2002 | 795 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 335 | 0.090 |
Why?
|
| Cerebellar Ataxia | 1 | 2011 | 65 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2010 | 15 | 0.090 |
Why?
|
| Xeroderma Pigmentosum Group A Protein | 1 | 2010 | 3 | 0.090 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 22 | 0.090 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 577 | 0.090 |
Why?
|
| Models, Animal | 2 | 2009 | 466 | 0.090 |
Why?
|
| Mice, Inbred Strains | 6 | 1998 | 312 | 0.090 |
Why?
|
| Genetic Variation | 1 | 2017 | 1492 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2010 | 30 | 0.090 |
Why?
|
| Germ Cells | 1 | 2011 | 192 | 0.090 |
Why?
|
| Kidney Neoplasms | 1 | 2014 | 435 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2010 | 65 | 0.080 |
Why?
|
| Antigens, Nuclear | 1 | 2010 | 61 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1260 | 0.080 |
Why?
|
| Gene Expression | 6 | 2016 | 1569 | 0.080 |
Why?
|
| Blotting, Southern | 8 | 2004 | 215 | 0.080 |
Why?
|
| Time Factors | 7 | 2007 | 6256 | 0.080 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 605 | 0.080 |
Why?
|
| Mammary Tumor Virus, Mouse | 3 | 1996 | 106 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2006 | 95 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2004 | 519 | 0.080 |
Why?
|
| Cocarcinogenesis | 2 | 2000 | 23 | 0.080 |
Why?
|
| Heat-Shock Proteins | 2 | 2013 | 194 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 2 | 2000 | 27 | 0.080 |
Why?
|
| Karyotyping | 4 | 2015 | 330 | 0.080 |
Why?
|
| RNA-Directed DNA Polymerase | 6 | 1995 | 46 | 0.080 |
Why?
|
| Cell Count | 2 | 2006 | 251 | 0.080 |
Why?
|
| Physical Conditioning, Animal | 1 | 2009 | 95 | 0.080 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 114 | 0.070 |
Why?
|
| G2 Phase | 2 | 2000 | 45 | 0.070 |
Why?
|
| Histiocytic Disorders, Malignant | 1 | 2007 | 2 | 0.070 |
Why?
|
| Genes, Viral | 3 | 1989 | 184 | 0.070 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2007 | 17 | 0.070 |
Why?
|
| Skin | 3 | 2013 | 513 | 0.070 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 53 | 0.070 |
Why?
|
| Gene Products, tat | 3 | 1997 | 28 | 0.070 |
Why?
|
| Papilloma | 2 | 2000 | 25 | 0.070 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 768 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2014 | 998 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 286 | 0.070 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2007 | 62 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2007 | 50 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 247 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 459 | 0.070 |
Why?
|
| Epigenesis, Genetic | 2 | 2013 | 675 | 0.070 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 573 | 0.070 |
Why?
|
| Receptors, Notch | 1 | 2009 | 203 | 0.070 |
Why?
|
| Kinetics | 2 | 2007 | 1321 | 0.070 |
Why?
|
| Ubiquitin | 1 | 2007 | 142 | 0.070 |
Why?
|
| Pyridines | 2 | 2005 | 225 | 0.070 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2006 | 36 | 0.070 |
Why?
|
| Quinolines | 1 | 2007 | 95 | 0.070 |
Why?
|
| Cell Transformation, Viral | 2 | 2006 | 106 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 60 | 0.070 |
Why?
|
| Adenoma | 2 | 2000 | 135 | 0.070 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2006 | 56 | 0.060 |
Why?
|
| Hepatitis B virus | 3 | 2014 | 136 | 0.060 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2005 | 41 | 0.060 |
Why?
|
| RNA Interference | 1 | 2007 | 504 | 0.060 |
Why?
|
| Biochemistry | 1 | 2005 | 11 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 377 | 0.060 |
Why?
|
| Mice, SCID | 2 | 2017 | 570 | 0.060 |
Why?
|
| Virus Replication | 5 | 1997 | 602 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2005 | 145 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2015 | 696 | 0.060 |
Why?
|
| Mutation, Missense | 2 | 2015 | 869 | 0.060 |
Why?
|
| Foreign Bodies | 1 | 2006 | 104 | 0.060 |
Why?
|
| Repressor Proteins | 3 | 2005 | 821 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2005 | 77 | 0.060 |
Why?
|
| Oxidative Stress | 2 | 2010 | 814 | 0.060 |
Why?
|
| Cloning, Molecular | 5 | 2003 | 892 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 2 | 1995 | 64 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 756 | 0.060 |
Why?
|
| Uracil | 1 | 2004 | 14 | 0.060 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 66 | 0.060 |
Why?
|
| Threonine | 1 | 2004 | 59 | 0.060 |
Why?
|
| Gene Transfer Techniques | 2 | 2003 | 358 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2004 | 187 | 0.060 |
Why?
|
| Keratins | 2 | 2000 | 55 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 2007 | 338 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2006 | 698 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 356 | 0.060 |
Why?
|
| Indoles | 1 | 2005 | 183 | 0.060 |
Why?
|
| Chromosomes | 2 | 2004 | 199 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2015 | 333 | 0.050 |
Why?
|
| Genes | 1 | 2004 | 444 | 0.050 |
Why?
|
| Cell Movement | 2 | 2017 | 834 | 0.050 |
Why?
|
| 1,2-Dimethylhydrazine | 1 | 2003 | 5 | 0.050 |
Why?
|
| Genes, fos | 2 | 2000 | 16 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 79 | 0.050 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 3 | 1997 | 30 | 0.050 |
Why?
|
| Sex Factors | 1 | 2006 | 1266 | 0.050 |
Why?
|
| Hyperplasia | 3 | 1997 | 209 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 463 | 0.050 |
Why?
|
| Biomarkers | 2 | 2009 | 2974 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2017 | 1217 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2014 | 788 | 0.050 |
Why?
|
| Telomere | 2 | 2010 | 207 | 0.050 |
Why?
|
| Wound Healing | 2 | 2006 | 456 | 0.050 |
Why?
|
| Flow Cytometry | 4 | 2013 | 804 | 0.050 |
Why?
|
| Body Constitution | 1 | 2002 | 37 | 0.050 |
Why?
|
| HIV | 1 | 2003 | 180 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 34 | 0.050 |
Why?
|
| Hair | 1 | 2002 | 22 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 656 | 0.050 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 1992 | 37 | 0.050 |
Why?
|
| Mitotic Index | 2 | 1999 | 19 | 0.050 |
Why?
|
| Chromosome Deletion | 2 | 2015 | 640 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 872 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 807 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2022 | 155 | 0.050 |
Why?
|
| Animal Testing Alternatives | 1 | 2001 | 3 | 0.050 |
Why?
|
| Nuclease Protection Assays | 1 | 2000 | 1 | 0.050 |
Why?
|
| Cyclin G | 1 | 2000 | 2 | 0.050 |
Why?
|
| Cyclin G1 | 1 | 2000 | 2 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 471 | 0.050 |
Why?
|
| Cyclin B1 | 1 | 2000 | 9 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2003 | 606 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2022 | 224 | 0.050 |
Why?
|
| Cyclin B | 1 | 2000 | 23 | 0.050 |
Why?
|
| Caseins | 1 | 2000 | 62 | 0.050 |
Why?
|
| Organ Size | 1 | 2002 | 422 | 0.040 |
Why?
|
| Gene Products, rev | 2 | 1997 | 11 | 0.040 |
Why?
|
| Spermatogenesis | 1 | 2002 | 171 | 0.040 |
Why?
|
| Osteoporosis | 1 | 2002 | 116 | 0.040 |
Why?
|
| Epidermis | 2 | 2000 | 59 | 0.040 |
Why?
|
| rev Gene Products, Human Immunodeficiency Virus | 2 | 1997 | 17 | 0.040 |
Why?
|
| Genomics | 2 | 2021 | 1486 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 384 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2000 | 109 | 0.040 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2000 | 21 | 0.040 |
Why?
|
| Cyclin E | 1 | 2000 | 30 | 0.040 |
Why?
|
| Centrosome | 1 | 2000 | 34 | 0.040 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2000 | 118 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2000 | 29 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2005 | 317 | 0.040 |
Why?
|
| Intestinal Neoplasms | 1 | 2000 | 39 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 693 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2002 | 263 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1694 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 519 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2000 | 73 | 0.040 |
Why?
|
| Oncogene Protein p21(ras) | 2 | 1996 | 9 | 0.040 |
Why?
|
| Microsatellite Repeats | 2 | 2016 | 219 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 1999 | 151 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 1999 | 61 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2000 | 1690 | 0.040 |
Why?
|
| Phosphotransferases | 1 | 1999 | 41 | 0.040 |
Why?
|
| Neurofibromin 2 | 1 | 1998 | 7 | 0.040 |
Why?
|
| Lymphocyte Activation | 3 | 2015 | 684 | 0.040 |
Why?
|
| WT1 Proteins | 1 | 1998 | 27 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 754 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2005 | 70 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 1998 | 44 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 1998 | 35 | 0.040 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2000 | 146 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 1998 | 79 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 3 | 1996 | 767 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 20 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 1998 | 42 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 1998 | 68 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2002 | 468 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 94 | 0.040 |
Why?
|
| Actins | 1 | 2000 | 343 | 0.040 |
Why?
|
| Genes, tat | 2 | 1995 | 10 | 0.040 |
Why?
|
| Teratogens | 1 | 1999 | 87 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 370 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2018 | 63 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 359 | 0.040 |
Why?
|
| RNA, Viral | 2 | 1997 | 538 | 0.040 |
Why?
|
| Stomach | 1 | 2000 | 273 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 1999 | 240 | 0.040 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 31 | 0.040 |
Why?
|
| 3T3 Cells | 4 | 2003 | 129 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 1995 | 54 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 1998 | 268 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 70 | 0.040 |
Why?
|
| Diet | 1 | 2004 | 1134 | 0.040 |
Why?
|
| von Willebrand Factor | 1 | 1999 | 196 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 13 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1996 | 135 | 0.040 |
Why?
|
| Algorithms | 2 | 2014 | 1609 | 0.040 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 1994 | 56 | 0.040 |
Why?
|
| Genome, Viral | 2 | 2014 | 168 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 106 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1997 | 132 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 58 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2016 | 33 | 0.030 |
Why?
|
| Oncogene Proteins v-fos | 1 | 1996 | 1 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 1998 | 267 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1996 | 37 | 0.030 |
Why?
|
| Incidence | 2 | 2002 | 3074 | 0.030 |
Why?
|
| Kidney | 2 | 2002 | 1344 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 1999 | 995 | 0.030 |
Why?
|
| Retroviridae Infections | 1 | 1996 | 10 | 0.030 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 1996 | 10 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 1997 | 170 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2016 | 289 | 0.030 |
Why?
|
| Fetus | 1 | 2000 | 583 | 0.030 |
Why?
|
| Ampulla of Vater | 1 | 2016 | 16 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 216 | 0.030 |
Why?
|
| Gene Products, pol | 2 | 1995 | 5 | 0.030 |
Why?
|
| Kainic Acid | 1 | 1996 | 25 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2007 | 371 | 0.030 |
Why?
|
| Genetic Drift | 1 | 2015 | 22 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1996 | 100 | 0.030 |
Why?
|
| DNA Replication | 2 | 2013 | 350 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 1995 | 76 | 0.030 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 1995 | 19 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 354 | 0.030 |
Why?
|
| Genes, rev | 1 | 1995 | 5 | 0.030 |
Why?
|
| Astrocytes | 2 | 1995 | 252 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 28 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2015 | 133 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 101 | 0.030 |
Why?
|
| Ataxia Telangiectasia | 1 | 1995 | 15 | 0.030 |
Why?
|
| Viral Proteins | 2 | 1995 | 349 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1997 | 350 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1996 | 134 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2015 | 54 | 0.030 |
Why?
|
| Cell Death | 1 | 1996 | 240 | 0.030 |
Why?
|
| Cleavage Stimulation Factor | 1 | 2014 | 3 | 0.030 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 1 | 1994 | 2 | 0.030 |
Why?
|
| Gene Products, vif | 1 | 1994 | 4 | 0.030 |
Why?
|
| Serial Passage | 1 | 1994 | 19 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1994 | 87 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 1995 | 133 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 80 | 0.030 |
Why?
|
| Japan | 1 | 2014 | 133 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 887 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 124 | 0.030 |
Why?
|
| Rats | 3 | 2013 | 3685 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 192 | 0.030 |
Why?
|
| Response Elements | 1 | 2014 | 97 | 0.030 |
Why?
|
| Polyadenylation | 1 | 2014 | 55 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 130 | 0.030 |
Why?
|
| Software Design | 1 | 2014 | 24 | 0.030 |
Why?
|
| Toxicology | 1 | 1994 | 9 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 142 | 0.030 |
Why?
|
| Pituitary Neoplasms | 1 | 1995 | 84 | 0.030 |
Why?
|
| Dimethylnitrosamine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Proviruses | 2 | 1996 | 17 | 0.030 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 1994 | 59 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1993 | 37 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 1993 | 54 | 0.030 |
Why?
|
| RNA, Antisense | 1 | 1993 | 35 | 0.030 |
Why?
|
| Oligonucleotides | 2 | 1991 | 89 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 2013 | 17 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2015 | 325 | 0.030 |
Why?
|
| Pyrimidine Dimers | 1 | 2013 | 2 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2000 | 68 | 0.030 |
Why?
|
| Proteins | 1 | 1998 | 1042 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 559 | 0.030 |
Why?
|
| Glioblastoma | 1 | 1997 | 333 | 0.030 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2013 | 40 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 211 | 0.030 |
Why?
|
| Escherichia coli Proteins | 1 | 1995 | 302 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 267 | 0.030 |
Why?
|
| Fibrosis | 1 | 1995 | 436 | 0.030 |
Why?
|
| Astrocytoma | 1 | 1994 | 103 | 0.030 |
Why?
|
| Androgens | 1 | 1995 | 275 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2014 | 241 | 0.030 |
Why?
|
| Defective Viruses | 2 | 1995 | 18 | 0.030 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2013 | 62 | 0.030 |
Why?
|
| Autoantigens | 1 | 2013 | 119 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 862 | 0.030 |
Why?
|
| Genetic Linkage | 2 | 2007 | 452 | 0.030 |
Why?
|
| Protein Binding | 1 | 2016 | 1748 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1995 | 198 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 199 | 0.030 |
Why?
|
| Mice, Inbred CBA | 1 | 1992 | 30 | 0.020 |
Why?
|
| Age Factors | 1 | 1999 | 2815 | 0.020 |
Why?
|
| Prostate | 1 | 1995 | 431 | 0.020 |
Why?
|
| DNA Transposable Elements | 2 | 1994 | 177 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 1993 | 289 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 459 | 0.020 |
Why?
|
| Cell Survival | 1 | 1994 | 807 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 426 | 0.020 |
Why?
|
| Blastocyst | 1 | 1992 | 78 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 472 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 1994 | 621 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2014 | 327 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 4727 | 0.020 |
Why?
|
| Mutagenicity Tests | 1 | 2011 | 36 | 0.020 |
Why?
|
| Hyperpigmentation | 1 | 2011 | 13 | 0.020 |
Why?
|
| Pediatrics | 1 | 2021 | 1157 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2001 | 3364 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 509 | 0.020 |
Why?
|
| Glioma | 1 | 1995 | 499 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2016 | 0.020 |
Why?
|
| Ku Autoantigen | 1 | 2010 | 21 | 0.020 |
Why?
|
| Retroviruses, Simian | 1 | 1990 | 3 | 0.020 |
Why?
|
| Templates, Genetic | 1 | 1990 | 97 | 0.020 |
Why?
|
| Hippocampus | 1 | 1996 | 825 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2010 | 62 | 0.020 |
Why?
|
| Haploinsufficiency | 1 | 2011 | 260 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2010 | 79 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 53 | 0.020 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 1990 | 92 | 0.020 |
Why?
|
| Growth Disorders | 1 | 2011 | 209 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 942 | 0.020 |
Why?
|
| Retroviridae Proteins | 1 | 1988 | 13 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2010 | 410 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1176 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 61 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 2 | 1996 | 369 | 0.020 |
Why?
|
| Endonucleases | 1 | 1988 | 54 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3256 | 0.020 |
Why?
|
| Cellular Reprogramming | 1 | 2010 | 116 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 435 | 0.020 |
Why?
|
| Reference Values | 2 | 2003 | 709 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2007 | 31 | 0.020 |
Why?
|
| Epithelial Cells | 2 | 2003 | 902 | 0.020 |
Why?
|
| Chromosomes, Mammalian | 1 | 2007 | 41 | 0.020 |
Why?
|
| Plasmids | 1 | 1988 | 514 | 0.020 |
Why?
|
| Anemia | 1 | 2011 | 341 | 0.020 |
Why?
|
| P-Selectin | 1 | 2007 | 77 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 259 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2000 | 623 | 0.020 |
Why?
|
| Autophagy | 1 | 2010 | 393 | 0.020 |
Why?
|
| Dermis | 1 | 2006 | 24 | 0.020 |
Why?
|
| Body Composition | 1 | 2009 | 521 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 396 | 0.020 |
Why?
|
| SAP90-PSD95 Associated Proteins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Discs Large Homolog 1 Protein | 1 | 2006 | 8 | 0.020 |
Why?
|
| Child | 3 | 2015 | 24417 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 1010 | 0.020 |
Why?
|
| Adult | 4 | 2015 | 29303 | 0.020 |
Why?
|
| Multigene Family | 1 | 2007 | 298 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 392 | 0.020 |
Why?
|
| Biopolymers | 1 | 2005 | 20 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 1996 | 14 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1995 | 1532 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 721 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2006 | 73 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1478 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 5086 | 0.020 |
Why?
|
| Methylation | 1 | 2005 | 226 | 0.020 |
Why?
|
| Hemangiosarcoma | 1 | 2005 | 39 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2006 | 445 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2006 | 124 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 458 | 0.020 |
Why?
|
| Mitochondria | 1 | 2010 | 691 | 0.010 |
Why?
|
| Animals, Newborn | 2 | 2000 | 1005 | 0.010 |
Why?
|
| Glycine | 1 | 2005 | 169 | 0.010 |
Why?
|
| Protein Transport | 1 | 2006 | 368 | 0.010 |
Why?
|
| Steroids | 1 | 2005 | 203 | 0.010 |
Why?
|
| DNA Adducts | 1 | 2005 | 78 | 0.010 |
Why?
|
| Precancerous Conditions | 2 | 2000 | 283 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 426 | 0.010 |
Why?
|
| Imidazoles | 1 | 2005 | 194 | 0.010 |
Why?
|
| Luciferases | 2 | 1995 | 136 | 0.010 |
Why?
|
| Hemangioma | 1 | 2005 | 95 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2005 | 82 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 340 | 0.010 |
Why?
|
| Chromatin | 1 | 2007 | 556 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 287 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 458 | 0.010 |
Why?
|
| Ecdysterone | 1 | 2003 | 2 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1241 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2003 | 14 | 0.010 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2003 | 35 | 0.010 |
Why?
|
| Adolescent | 2 | 2015 | 19269 | 0.010 |
Why?
|
| Arginine | 1 | 2005 | 332 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 173 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 126 | 0.010 |
Why?
|
| Thiazoles | 1 | 2003 | 98 | 0.010 |
Why?
|
| Progesterone | 1 | 2005 | 628 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 1982 | 32 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1997 | 326 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 579 | 0.010 |
Why?
|
| Hair Color | 1 | 2002 | 12 | 0.010 |
Why?
|
| Gene Library | 1 | 2003 | 220 | 0.010 |
Why?
|
| Breast | 1 | 2003 | 214 | 0.010 |
Why?
|
| Fatty Liver | 1 | 2003 | 179 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 833 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 8939 | 0.010 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2000 | 6 | 0.010 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2000 | 15 | 0.010 |
Why?
|
| Forelimb | 1 | 2000 | 14 | 0.010 |
Why?
|
| Integrin beta1 | 1 | 2000 | 54 | 0.010 |
Why?
|
| CD18 Antigens | 1 | 2000 | 49 | 0.010 |
Why?
|
| Pepsinogen A | 1 | 2000 | 17 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 22 | 0.010 |
Why?
|
| Nocodazole | 1 | 2000 | 14 | 0.010 |
Why?
|
| Aged | 1 | 2018 | 19349 | 0.010 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2000 | 64 | 0.010 |
Why?
|
| Piroxicam | 1 | 2000 | 2 | 0.010 |
Why?
|
| Mice, Inbred ICR | 1 | 2000 | 154 | 0.010 |
Why?
|
| Eflornithine | 1 | 2000 | 15 | 0.010 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2000 | 8 | 0.010 |
Why?
|
| Benzene | 1 | 2000 | 24 | 0.010 |
Why?
|
| Genes, APC | 1 | 2000 | 13 | 0.010 |
Why?
|
| Osteocalcin | 1 | 2000 | 42 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2000 | 164 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1980 | 120 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2000 | 50 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1071 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 139 | 0.010 |
Why?
|
| Tubulin | 1 | 2000 | 102 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2000 | 86 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 2000 | 83 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2000 | 140 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 211 | 0.010 |
Why?
|
| United States | 1 | 2014 | 10739 | 0.010 |
Why?
|
| Middle Aged | 1 | 2018 | 26316 | 0.010 |
Why?
|
| Chimera | 1 | 1998 | 88 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2000 | 304 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 2000 | 485 | 0.010 |
Why?
|
| Motor Activity | 1 | 2000 | 524 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 1997 | 56 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1997 | 116 | 0.010 |
Why?
|
| Mitomycin | 1 | 1996 | 49 | 0.010 |
Why?
|
| Mitogens | 1 | 1996 | 30 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1996 | 60 | 0.010 |
Why?
|
| Mink Cell Focus-Inducing Viruses | 1 | 1996 | 1 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 1996 | 1 | 0.010 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1996 | 6 | 0.010 |
Why?
|
| RNA Polymerase III | 1 | 1996 | 39 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1996 | 99 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1996 | 84 | 0.010 |
Why?
|
| Lac Repressors | 1 | 1995 | 14 | 0.010 |
Why?
|
| Bacteriophage lambda | 1 | 1995 | 27 | 0.010 |
Why?
|
| Gene Products, gag | 1 | 1995 | 19 | 0.010 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1995 | 12 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1996 | 123 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 1995 | 4 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1995 | 29 | 0.010 |
Why?
|
| Protamine Kinase | 1 | 1995 | 7 | 0.010 |
Why?
|
| Mutagenesis, Insertional | 1 | 1996 | 147 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 1995 | 28 | 0.010 |
Why?
|
| Fibrosarcoma | 1 | 1995 | 28 | 0.010 |
Why?
|
| Transgenes | 1 | 1996 | 336 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1997 | 295 | 0.010 |
Why?
|
| Inhibins | 1 | 1995 | 87 | 0.010 |
Why?
|
| Orchiectomy | 1 | 1995 | 49 | 0.010 |
Why?
|
| Oncogenic Viruses | 1 | 1975 | 17 | 0.010 |
Why?
|
| RNA Viruses | 1 | 1975 | 36 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1995 | 77 | 0.010 |
Why?
|
| Tyrosine | 1 | 1995 | 152 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 251 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1995 | 176 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 1997 | 382 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1995 | 329 | 0.010 |
Why?
|
| Integrases | 1 | 1995 | 161 | 0.010 |
Why?
|
| Zidovudine | 1 | 1994 | 22 | 0.010 |
Why?
|
| Binding Sites | 1 | 1997 | 1294 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1994 | 172 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 1993 | 79 | 0.010 |
Why?
|
| Genome | 1 | 1996 | 475 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1993 | 188 | 0.010 |
Why?
|
| Infant | 1 | 2007 | 12439 | 0.010 |
Why?
|
| Genes, env | 1 | 1991 | 9 | 0.010 |
Why?
|
| Peptides | 1 | 1995 | 790 | 0.010 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 1991 | 20 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2007 | 14021 | 0.010 |
Why?
|
| Codon | 1 | 1991 | 96 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1992 | 314 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1992 | 395 | 0.010 |
Why?
|
| RNA | 1 | 1995 | 568 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1995 | 527 | 0.010 |
Why?
|
| HIV Seropositivity | 1 | 1991 | 117 | 0.010 |
Why?
|
| Syndrome | 1 | 1993 | 1117 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1995 | 884 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1991 | 406 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2007 | 16195 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1988 | 80 | 0.000 |
Why?
|
| DNA Probes | 1 | 1988 | 124 | 0.000 |
Why?
|
| China | 1 | 1988 | 242 | 0.000 |
Why?
|
| Pregnancy | 1 | 2001 | 7224 | 0.000 |
Why?
|
| DNA, Recombinant | 1 | 1987 | 100 | 0.000 |
Why?
|
| Helper Viruses | 1 | 1987 | 45 | 0.000 |
Why?
|
| Coturnix | 1 | 1982 | 5 | 0.000 |
Why?
|
| Avian Leukosis Virus | 1 | 1982 | 14 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1995 | 8158 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 2996 | 0.000 |
Why?
|
| Risk Factors | 1 | 1994 | 10107 | 0.000 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1975 | 15 | 0.000 |
Why?
|
| Chromatography | 1 | 1975 | 43 | 0.000 |
Why?
|
| Polyvinyls | 1 | 1975 | 13 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1975 | 257 | 0.000 |
Why?
|
| Culture Media | 1 | 1975 | 183 | 0.000 |
Why?
|